Home › Services › Rabbit mAb Humanization

Rabbit antibodies bind better than mouse ones. Are they harder to humanize?

No — in our experience they are easier, which is not the intuition most people bring. Rabbit monoclonals usually derive from a small number of germlines with well-defined canonical CDR structures, so the framework context a graft has to reproduce is far more predictable than for a mouse antibody drawn from a diverse repertoire. Abwiz Bio applies RabWiz™ and STEM™ know-how to humanize while preserving affinity and specificity, and this is routine work in our own therapeutic pipeline rather than an occasional service — our COVID therapeutic mAb went through exactly this route. You keep the high intrinsic affinity that made you choose a rabbit lead in the first place.

Why start from a rabbit antibody at all

Rabbit repertoires carry unusually high CDR diversity in both heavy and light chains together with high intrinsic affinity, which is why rabbit monoclonals routinely reach affinities that mouse campaigns struggle toward. They also see epitopes mouse antibodies miss: the phylogenetic distance from human is greater, so conserved human epitopes that are effectively self to a mouse remain immunogenic in a rabbit. For targets that are highly conserved across mammals, that difference decides whether a campaign produces anything at all.

The historical objection was that rabbit leads were harder to take forward clinically. That was a tooling problem, not a biological one, and it has been solved.

Why rabbit humanization is comparatively tractable

• Few germlines, defined canonical structures. Because rabbit mAbs concentrate in a limited set of germlines with well-characterized canonical CDR conformations, the framework support a given loop needs is largely known in advance. Back-mutation becomes a targeted decision rather than an empirical hunt across the Vernier zone.
• Accumulated know-how. Having run rabbit discovery through RabWiz™ across many campaigns, the same framework and back-mutation choices recur, so each new program starts from a solved template rather than from first principles.
• Affinity headroom. Rabbit leads typically start at higher affinity than mouse ones, so even where a graft costs some binding, the humanized molecule frequently remains in a useful range — and STEM™ recovers the difference when it does not.
• Light-chain handling. About 90% of rabbit light chains carry extra cysteines in FR3L and CK1. Our phagemid was designed around exactly this feature for rabbit Fab display, and the same understanding informs how the chains are handled through humanization.

How the campaign runs

The workflow parallels mouse humanization: acceptor germline framework selection based on similarity and canonical-class compatibility, structure-guided back-mutation of Vernier and VH/VL interface positions evaluated with a local AlphaFold instance plus germline and structural bioinformatics, then STEM™ affinity recovery on your antigen where the graft costs binding. STEM™ CDR libraries designed from human amino-acid usage can humanize the CDRs themselves, addressing immunogenicity that framework grafting alone leaves behind. Thermostability and polyreactivity filters run at every stage.

Because a STEM™ selection is running anyway, other properties are commonly folded into the same campaign: cyno or mouse cross-reactivity so toxicology reads on the actual candidate rather than a surrogate, developability optimization, expression rescue, and pH-dependent release.

If you do not yet have a rabbit lead, we run de novo rabbit monoclonal discovery (RabWiz™) with immune phage libraries of 5×10⁹–10¹⁰, and can carry the campaign straight through to a humanized, engineered clone. If you need a quick function or isotype check before committing, chimeric antibody generation is faster.

You receive

• Humanized IgG
• Binding and function data benchmarked against the parent rabbit antibody
• Full VH/VL sequences
• Documentation of framework choice and back-mutations made
• No downstream royalties, stage-gated approval before each next step

Frequently asked questions

Can rabbit monoclonal antibodies be humanized for therapeutic use?

Yes, and comparatively predictably. Rabbit mAbs usually derive from a few germlines with well-defined canonical CDR structures, so the framework context a graft must reproduce is largely known in advance. It is routine work in the Abwiz Bio therapeutic pipeline, including our COVID therapeutic monoclonal.

Is rabbit humanization harder than mouse humanization?

In our experience it is more tractable, because the restricted germline usage and defined canonical CDR conformations make back-mutation a targeted decision rather than an empirical search. Rabbit leads also typically start from higher affinity, which leaves more headroom if the graft costs some binding.

Why use a rabbit antibody rather than a mouse one?

Rabbit repertoires carry high CDR diversity in both chains together with high intrinsic affinity, and the greater phylogenetic distance from human means conserved human epitopes that are effectively self to a mouse remain immunogenic in a rabbit. For highly conserved targets this can decide whether a campaign yields anything at all.

Will the humanized antibody keep the parent affinity?

Preserving affinity and specificity is the design goal, and where the graft costs binding, STEM affinity maturation recovers it by selection on your antigen. Delivered clones are benchmarked against the parent rabbit antibody so the comparison is measured rather than assumed.

What do you need to start?

The VH/VL amino-acid sequence of the rabbit antibody and the antigen. If you do not have a lead yet, we can run de novo rabbit discovery and carry it through to a humanized clone in one program. Contact info@abwizbio.com for a scoped quote.